BTG3 and metastatic malignant neoplasm: BTG3 expression was detectable in gastric non-neoplastic mucosa (83.3%, 474/569), primary cancer (33.1%, 203/613), and metastatic cancer in lymph node (31.7%, 57/180), respectively.